Kirsten rat sarcoma (KRAS)-driven cancer treatment is an important clinical need that remains largely unmet due to limited targeted drug efficacy of key downstream effectors, including MAPK and PI3K-AKT pathways. The gene discussed is KRAS; the disease is cancer.